{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:25:45Z","timestamp":1787214345996,"version":"build-2736575974"},"reference-count":84,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>A lifelong career devoted to the development of specific antiviral agents eventually yielded, besides (almost) 3000 publications, about ten antiviral compounds that were approved and marketed as antiviral drugs, i.e., DHPA (Duviragel\u00ae), BVDU (Zostex\u00ae, Mevir\u00ae, Brivir\u00ae\u2026), VACV (Zelitrex\u00ae, Valtrex\u00ae), d4T (Stavudine\u00ae), emivirine (Coactinon\u00ae), rilpivirine (Edurant\u00ae), HPMPC (Vistide\u00ae), PMEA (Hepsera\u00ae), tenofovir (Viread\u00ae) and AMD-3100 (Mozobil\u00ae), with the latter as a hematopoietic stem cell mobilizer. The targeted viruses for these compounds were herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), and hepatitis B virus (HBV). For other viruses, such as filo-, rhabdo-, arena-, myxo-, polyoma- and papillomaviruses, strategies have been elaborated that should facilitate future developments of antiviral drugs.<\/jats:p>","DOI":"10.3390\/molecules31162896","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:10:20Z","timestamp":1787213420000},"page":"2896","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["On the Verge of the 3000th Publication: Reflections on Deceptions, Successes and Perspectives"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/jvi.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/jvi.2.9.886-893.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/am.16.9.1314-1319.1968","article-title":"Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus","volume":"16","year":"1968","journal-title":"Appl. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/214416a0","article-title":"Induction of circulating interferon by synthetic anionic polymers of known composition","volume":"214","author":"Merigan","year":"1967","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM196712142772403","article-title":"Interferon induction in man by a synthetic polyanion of defined composition","volume":"277","author":"Merigan","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/2221148a0","article-title":"Requirement of a stable secondary structure for the antiviral activity of polynucleotides","volume":"222","author":"Merigan","year":"1969","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.165.3898.1137","article-title":"Interferon induction increased through chemical modification of a synthetic polyribonucleotide","volume":"165","author":"Eckstein","year":"1969","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI106374","article-title":"The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice","volume":"49","author":"Nuwer","year":"1970","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-2836(71)90086-6","article-title":"Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides","volume":"56","author":"Wells","year":"1971","journal-title":"J. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.58.3.1004","article-title":"Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes","volume":"58","author":"Field","year":"1967","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3181\/00379727-137-35627","article-title":"Moloney sarcoma virus-induced tumors in mice: Inhibition or stimulation by (poly rI)\u00b7(poly rC)","volume":"137","author":"Merigan","year":"1971","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1073\/pnas.79.9.2768","article-title":"Secretory proteins induced in human fibroblasts under conditions used for the production of interferon b","volume":"79","author":"Content","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/2261211a0","article-title":"Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of Rous Sarcoma Virus","volume":"226","author":"Temin","year":"1970","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/2261209a0","article-title":"Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses","volume":"226","author":"Baltimore","year":"1970","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3835(79)90017-X","article-title":"Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses","volume":"8","year":"1979","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2\u2032,3\u2032-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","article-title":"Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi\u2019s sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo","volume":"2","author":"Broder","year":"1985","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jo01030a546","article-title":"Nucleosides. V. The monomesylates of 1-(2\u2032-deoxy-\u03b2-D-lyxofuranosyl)thymine1,2","volume":"29","author":"Horwitz","year":"1964","journal-title":"J. Org. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.me.21.020170.000313","article-title":"Current concepts of interferon and interferon induction","volume":"21","author":"Merigan","year":"1970","journal-title":"Annu. Rev. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2032,3\u2032-dideoxythymidine and its 2\u2032,3-unsaturated derivative (2\u2032,3\u2032-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90287-5","article-title":"Potent and selective in vitro activity of 3\u2032-deoxythymidin-2\u2032-ene (3\u2032-deoxy-2\u2032,3\u2032-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Lin","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","article-title":"Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2\u2032-deoxy-3\u2032-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog","volume":"35","author":"Soudeyns","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/AAC.41.5.1099","article-title":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89","volume":"41","author":"Faletto","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.37.10.2206","article-title":"Infectious amplification of wild-type human immunodeficiency virus from patients\u2019 lymphocytes and modulation by reverse transcriptase inhibitors in vitro","volume":"37","author":"Mathez","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1099\/0022-1317-56-2-259","article-title":"Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice","volume":"56","author":"Field","year":"1981","journal-title":"J. Gen. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archopht.1984.01040030118049","article-title":"Topical treatment of experimental herpes simplex keratouveitis with 2\u2032-O-glycylacyclovir","volume":"102","author":"Maudgal","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","article-title":"(E)-5-(2-Bromovinyl)-2\u2032-deoxyuridine: A potent and selective anti-herpes agent","volume":"76","author":"Descamps","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","first-page":"1178","article-title":"Oral (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine in severe herpes zoster","volume":"281","author":"Degreef","year":"1980","journal-title":"Br. Med. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/14.suppl_A.85","article-title":"The antiviral spectrum of (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine","volume":"14","year":"1984","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.200.4341.563","article-title":"(S)-9-(2,3-dihydroxypropyl)adenone: An aliphatic nucleoside analog with broad-spectrum antiviral activity","volume":"200","author":"Descamps","year":"1978","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Rosenberg","year":"1986","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1128\/AAC.34.7.1326","article-title":"Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro","volume":"34","author":"Yokota","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/AAC.35.2.394","article-title":"Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis","volume":"35","author":"Yokota","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jmv.1890450221","article-title":"Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine","volume":"45","author":"Snoeck","year":"1995","journal-title":"J. Med. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<219::AID-JMV13>3.0.CO;2-C","article-title":"Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]","volume":"54","author":"Snoeck","year":"1998","journal-title":"J. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1086\/318497","article-title":"Systemic cidofovir in papillomatosis","volume":"32","author":"Wellens","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-9071(200002)60:2<205::AID-JMV16>3.0.CO;2-8","article-title":"Cidofovir, a new approach for the treatment of Cervix Intraepithelial Neoplasia Grade III (CIN III)","volume":"60","author":"Snoeck","year":"2000","journal-title":"J. Med. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"De Clercq, E. (2022). Cidofovir for the treatment of molluscum contagiosum virus. Viruses, 14.","DOI":"10.3390\/v14112484"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jmv.1084","article-title":"A case of human orf in an immunocompromised patient treated successfully with cidofovir cream","volume":"64","author":"Geerinck","year":"2001","journal-title":"J. Med. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00001432-199812000-00014","article-title":"Specific therapies for human papilloma virus infections","volume":"11","author":"Snoeck","year":"1998","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1432-2277.2006.00430.x","article-title":"Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients","volume":"20","author":"Bonatti","year":"2007","journal-title":"Transpl. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.33696\/immunology.2.015","article-title":"Tenofovir at the crossroad of the therapy and prophylaxis of HIV and HBV infections","volume":"2","year":"2020","journal-title":"J. Cell. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0006-291X(89)92756-3","article-title":"Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative","volume":"165","author":"Baba","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/jm00132a002","article-title":"A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine","volume":"32","author":"Miyasaka","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1073\/pnas.88.4.1451","article-title":"An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4-benzodiazepin-2(1H)-one and -thione derivatives","volume":"88","author":"Debyser","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1073\/pnas.88.6.2356","article-title":"Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase","volume":"88","author":"Baba","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0026-895X(25)11080-8","article-title":"Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives","volume":"39","author":"Baba","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cbdv.200490012","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future","volume":"1","year":"2004","journal-title":"Chem. Biodivers."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.38.4.688","article-title":"Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro","volume":"38","author":"Baba","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"De Clercq, E. (2025). The meandrous route of rilpivirine in the search for the miraculous drug to treat HIV infections. Viruses, 17.","DOI":"10.3390\/v17070959"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"117125","DOI":"10.1016\/j.bcp.2025.117125","article-title":"Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention","volume":"240","author":"Zhang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1073\/pnas.89.12.5286","article-title":"Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event","volume":"89","author":"Yamamoto","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.38.4.668","article-title":"Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100","volume":"38","author":"Yamamoto","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","first-page":"1655","article-title":"The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pharmthera.2010.08.009","article-title":"Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers","volume":"128","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"De Clercq, E. (2015). AMD3100\/CXCR4 inhibitor. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00276"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2040206619829382","DOI":"10.1177\/2040206619829382","article-title":"Mozobil\u00ae (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration","volume":"27","year":"2019","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/MMBR.00065-15","article-title":"HIV genome-wide protein associations: A review of 30 years of research","volume":"80","author":"Li","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: Progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"De Clercq, E. (2022). FV-100 for the treatment of varicella-virus (VZV) infections: Quo vadis?. Viruses, 14.","DOI":"10.3390\/v14040770"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/asia.201900841","article-title":"New nucleoside analogues for the treatment of hemorrhagic fever virus infections","volume":"14","year":"2019","journal-title":"Chem. Asian J."},{"key":"ref_84","unstructured":"Di Santo, R., Garner, A.L., Georg, G.I., Meanwell, N.A., Saxena, A.K., Supuran, C.T., Zhang, A., Tschammer, N., and Poulsen, S.-A. (2026). Therapeutic options for hemorrhagic fever virus infections. Antiviral Agents Against Emerging Viruses, Springer."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/16\/2896\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:11:35Z","timestamp":1787213495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/16\/2896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":84,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["molecules31162896"],"URL":"https:\/\/doi.org\/10.3390\/molecules31162896","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}